Tekmira Begins Dosing Patients in Phase I Trial of Cancer Drug
December 23, 2010
Tekmira Begins Dosing Patients in Phase I Trial of Cancer Drug
The phase I trial is an open-label, multi-dose, dose-escalation study designed to
evaluate the safety, tolerability, and pharmacokinetics of TKM-PLK1, as well as determine the therapy's maximum tolerated dose.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Releases Phase I Cancer Drug Data, Plans Phase II Trial in Neuroendocrine Tumors
April 11, 2013 / Gene Silencing News - Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News - Tekmira Starts Phase I Study of Ebola Treatment
February 9, 2012 / Gene Silencing News - Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation
November 10, 2011 / Gene Silencing News